For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/the-latest-data-in-ckd-progression-10197

Summary
Emerging evidence highlights the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow CKD progression and reduce cardiovascular and kidney-related mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Yet, despite updated guidelines, these therapies remain underused. This program will explore the latest clinical data supporting the role of GLP-1 RAs in risk mitigation and provide practical strategies for implementing guideline-based treatment to reduce cardio-renal risk and improve outcomes in patients with T2D and CKD.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Discuss emerging data on GLP-1 RA therapy for CKD progression in T2D
• Implement guideline-based care to minimize CV risk and CKD progression

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an educational grant from Novo Nordisk.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.